Premium
Expanding the spectrum of genetic variants in the calcium‐sensing receptor ( CASR ) gene in hypercalcemic individuals
Author(s) -
Nissen Peter H.,
Rejnmark Lars
Publication year - 2019
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.14078
Subject(s) - calcium sensing receptor , endocrinology , medicine , calcium , missense mutation , hypercalciuria , hyperparathyroidism , primary hyperparathyroidism , exon , calcium metabolism , gene , chemistry , biology , genetics , mutation
Abstract Objective Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominantly inherited disorder with overlapping biochemistry profile with primary hyperparathyroidism (PHPT), making the correct diagnosis a challenge. The objective of the study was to evaluate the results of the clinical work‐up of a large group of hypercalcemic individuals. Design Cross‐sectional study. Patients Patients undergoing clinical work‐up of hypercalcemia. Measurements Molecular genetic analysis of the CASR gene and exon 2 of the AP2S1 gene. Plasma levels of ionized calcium and PTH as well as calcium creatinine clearance ratio (CCCR). Results A rare CASR variant was identified in 38 of 624 index patients (6.1%). A total of 18 CASR variants identified in this study were novel. No variants were identified in exon 2 of the AP2S1 gene. The majority of the variants (N = 16) were classified as likely pathogenic. The level of plasma calcium, plasma PTH and the CCCR was not affected by the type of variant (ie nonsense vs missense) (all P ‐values >.05). The CCCR was found to be significantly lower for variants in the transmembrane domain compared with variants located in the extracellular domain ( P < .05). Plasma levels of calcium and PTH were not associated with the location of the variant ( P > .05). Conclusions We expanded the spectrum of CASR variants in hypercalcemia with 18 novel variants, and suggest that the location of the CASR variant may affect calcium excretion as determined by the CCCR.